Figure 2: Combined loss of Tet2 and Tet3 results in expansion of myeloid cells with impaired lymphoid and erythroid differentiation.
From: Acute loss of TET function results in aggressive myeloid cancer in mice
(a) Representative photographs of femurs and tibiae at 4 weeks following pIpC injection. Tet2 KO, Tet2−/− Tet3fl/fl Mx1-Cre− or Tet2−/− Mx1-Cre+; Tet3 KO, Tet3fl/fl Mx1-Cre+. (b) Total cellularity of bone marrow was assessed at the indicated time points after pIpC injection (n=8∼11 per genotype at each time point). Means±s.e.m. are shown. **P<0.005 (Student's t-test). (c) Schematic representation of myeloid expansion and impaired lymphoid and erythroid development upon loss of Tet2 and Tet3. (d,e) Haematopoietic cell development upon simultaneous deletion of Tet2 and Tet3. Flow cytometry was performed to assess myeloid (Gr-1/Mac-1), erythroid (CD71/Ter-119) and lymphoid (B220/CD4/CD8) cell populations in the bone marrow (d, n=8 per each genotype) and spleen (e, n=6 per each genotype) of WT or DKO mice. Representative flow cytometry plots (left) and summary graphs (right) at 2∼2.5 weeks after pIpC injection are shown. For results at 4∼5 weeks, see Supplementary Figs 7 and 8. Means±s.e.m. are shown. **P<0.005, ***P<0.0005 (Student's t-test).
